ARTICLE | Company News
Caliber Biotherapeutics, ImmunGene, LLS cancer news
June 3, 2013 7:00 AM UTC
The society provided about $6 million in funds to Valor Biotherapeutics LLC, a JV between ImmunGene and Caliber, to develop IGN002 to treat non-Hodgkin's lymphoma (NHL) in patients who are resistant to standard therapy with Rituxan rituximab. The funding will support continued preclinical development and manufacturing of IGN002 as well as a Phase I trial, which is slated to begin in late 2015. IGN002 is interferon (IFN) alpha linked to an anti-CD20 mAb. The partners launched the JV in November to develop three mAb-IFN fusion protein candidates from ImmunGene with funding from Caliber to develop mAb-IFN fusion protein therapeutics for NHL, multiple myeloma and breast cancer. ...